Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
10 August 2023 - 9:00PM
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical
company aiming to transform the lives of patients by establishing
intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new
class of medicines, today announced the appointment of Gina Chapman
to its Board of Directors, effective September 1, 2023. Ms. Chapman
currently serves as President and Chief Executive Officer of CARGO
Therapeutics.
“Gina is a seasoned leader with more than thirty years of
experience driving the commercial and operational growth of
numerous biopharmaceutical companies,” said Dipal Doshi, President
and Chief Executive Officer of Entrada Therapeutics. “With a proven
track record of advancing therapeutics into the market, Gina’s
expertise will be crucial as we continue to progress Entrada’s
expanding pipeline of intracellular therapeutics.”
“I am honored to join the Board of Directors as
Entrada transitions into a clinical stage company with the
start of its first clinical trial in Duchenne muscular dystrophy
this September,” said Ms. Chapman. “The broad potential of
Entrada’s EEV platform to engage intracellular disease-causing
targets provides the opportunity to address diseases where
treatment options are unavailable or limited. I look forward to
working with Dipal and the Entrada team as we
advance EEV-therapeutics that address a diverse range of
serious diseases.”
As President and CEO of CARGO Therapeutics, Ms. Chapman is
leading the company’s development of next-generation CAR T-cell
therapies that address multiple mechanisms of resistance to deliver
therapies to people living with cancer. Since joining CARGO in May
of 2022, she has rapidly scaled the organization to advance its
pipeline, executed on critical manufacturing milestones and
successfully led her team to raise an upsized $200 million Series A
financing. Prior to joining CARGO, Ms. Chapman spent 15 years at
Genentech where she served as Senior Vice President, Business Unit
Head and was responsible for delivering the P&L across the
oncology, hematology, neurology, immunology, ophthalmology,
respiratory and rare diseases business units. Ms. Chapman began her
biopharma career with Syntex Laboratories and in 1994 she joined
Gilead Sciences as one of the first commercial hires where she was
responsible for the launch of the company’s first commercial
medicine and was a key contributor during its rapid growth from
clinical stage start-up to commercial enterprise.
About Entrada Therapeutics
Entrada Therapeutics is a biopharmaceutical
company aiming to transform the lives of patients by establishing a
new class of medicines, Endosomal Escape Vehicle
(EEV™)-therapeutics, to engage intracellular targets that have long
been considered inaccessible and undruggable. The Company’s EEV
therapeutics are designed to enable the efficient intracellular
delivery of a wide range of therapeutics into a variety of organs
and tissues, resulting in an improved therapeutic index. Through
its proprietary, highly versatile and modular EEV platform, Entrada
is building a robust development portfolio of RNA-, antibody- and
enzyme-based programs for the potential treatment of neuromuscular,
immunological, ocular and metabolic diseases, among others. The
Company’s lead oligonucleotide programs include ENTR-601-44 and
ENTR-601-45 for the potential treatment of people living with
Duchenne who are exon 44 and 45 skipping amenable, respectively, as
well as our partnered candidate ENTR-701 targeting myotonic
dystrophy type 1 (DM1).
For more information about Entrada, please visit
our website, www.entradatx.com, and follow us
on LinkedIn.
Investor and Media Contact Karla
MacDonald Chief Corporate Affairs Officer
kmacdonald@entradatx.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/2ca95a0d-13a0-4e6c-b3f4-191c05fc6798
Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From Apr 2024 to May 2024
Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From May 2023 to May 2024